Member Info for Heikkinen

Juho stated that he has ”marked year 2024” for the licensing deal so they are seeking licensing deal for that year. He also said that with the licensing deal the whole company would be sold (this is the general procedure when BP is starting the partnership with a small player like Faron).

Also: Selling permit application for the FDA on early 2025 and 6 month processing time for that.

Hi.

This was actually really something different from Faron. I would highly recommend you all to watch the interview. https://www.inderes.fi/fi/videot/faron-pharmaceuticals-sijoituskohteena-porssisijoittajan-viikko-1192023

If you don’t have good translator that can translate the speech, there is good summarise of the presentation in the Finnish forum (user Vino_Pino’s post):

https://keskustelut.inderes.fi/t/faron-pharmaceuticals-breakthrough-immunotherapies/2655/2541

Fun fact: Sirpa and Markku Jalkanen were celebrating at the president’s castle yesterday. Finland’s president invites people who have made an impact in their field of expertise. Most likely Sirpa was invited to the castle because she received the award from the Finnish Science Academy this year (Honorary award for her lifelong work).

Maybe Markku will receive invitation himself during the following years.

Yeah we have Independence Day here in Finland. Glad to see some positive news from Faron’s research and that the SP reacts to the news as well.

As always, we are slowly getting there and patience is still needed with this stock.

With all respect Covgaz. In previous post you looking for someone to comment on your posts. After somebody does that you start swearing and tell that don’t care at all what he/she is saying. Why should we bother to acknowledge you if you don’t care about our opinions? Why are you even on this board if you don’t care about what other people have to say?

If you ”know what’s coming and news won’t cut it” why don’t you sell your position and reallocate it somewhere else? I trust that you can find more profitable companies elsewhere.

In general I find it weird that you are so much locked-in to your purchase price. Always counting the difference to the breakeven point for some reason. Have you also considered inflation btw?

You are not public enemy on this board. People just have different opinion than you. But it’s your behaviour which is ignorant. Also, you are sometimes blaming people here to be working for Faron etc. which I find really absurd and honestly somewhat hilarious as well :D

”The guy with 19% is obviously eyeing a takeover here , I wonder how low he can get the price before he strikes.”

Haha. Of course this could be true as I don’t knowledge how to read minds. Anyhow, the guy is Timo Syrjälä. If you Covgaz want to do some background research (obviously you haven’t done this earlier regarding him) you can try to search with keywords like Elektrobit and Stonesoft. Timo has a pretty solid track record from these.

One of Timo’s current projects/investements is SSH communications. The two I mentioned above are older ones.

Timo will own 19,09%. Previously it was around 17% for Timo?

”Following the completion of the Placing, Mr. Syrjälä's total holding in the Company's shares, which includes his indirect holding through Acme, will be 10,548,498 shares, representing 19.09 per cent of the issued shares and votes of the Company following the Placing.”

Covgaz - Maybe better strategy for you would be dividing your purchases in Faron to different month/quarters etc.? It seems that you have put all in (all you can spare on Faron) at the first purchase and now can’t lower your average purchase price for this stock.

In my opinion that would smart strategy in uncertain stocks like this and in uncertain macroeconomics times like this. Buffett has said that he likes when stock prices are going down —> He can buy a piece of the company cheaper.

Regarding Faron I haven’t spotted any news that would have changed the basic fundamentals or would have signicantly changed my due diligence conclusions. Development has been slow but it’s always that in Pharma business and with new medicines.

Somehow I can’t relate to your hard dissapointment on SP not going North. IMO the current downward trend is more caused by inflation, rising interest rates and other uncertainties rather than Faron’s own actions. Luckily Faron has cheap loans from EIC and Business Finland in their balance sheet and soft fundings on top of those.

Dracula: No offence to you (or anyone else). Your comments have been fair and I respect your view. Based on your comments you have done the background checks etc well.

My previous post were more towarded for people who have, and have had, more negative point of view for Faron, for example Covgaz. My previous post was actually inspired by the shareholder letter written by Jeff Bezos from the time when Amazon’s stock dropped 80% in one year (around year 2000).

https://s2.q4cdn.com/299287126/files/doc_financials/annual/00ar_letter.pdf

Naturally my comments are also affected by me, an anonymous nickname at the board. IMO is always IMO, everyone has their own opinions (hopefully).

The famed investor Benjamin Graham said, ‘‘In the short term, the stock market is a voting machine. In the long term, it’s a weighing machine.’’

The weighing is still to come for Faron. Unfortunately the SP hasn’t followed the business value recently. I see that Faron is much better positioned now than for example 12 months ago (positive results, biomarker findings, bigger market potential, funding etc).

Luckily for me I am in no hurry to sell these stocks and I have a position with which I can sleep during the nights. Hopefully you can too. I would suggest to unlock and lock another target if having doubts. The disclaimers are there for a reason in all of the presentations.

Even though Faron released a RNS related to Traumakine, all that I can think of is the song from Hanoi Rocks - A Day Late, a Dollar Short.

No offence to their scientific contribution. That is awesome and they are doing important work. Hopefully they are able to convert all this to the market success / SP. After all, this is a listed company not a academic project funded only by charity funds.

Juho Jalkanen said that "We are pleased that the data was published". I think that they are still quite unpleased how the thhngs went and they really don't appreciate WHO. And Faron has every right to feel that way. False accusations are always false accusations and if one doens't provide any data to back those up.. well.. let's just say that one would be an excellent candidate for the minister position in the current Finnish government..

True, that would be VERY positive indicator in my perspective if we would have another well-known big investor from Finland investing in Faron!

It would also mitigate the little doubt that I have in my mind about Timo Syrjälä’s investment. As cancer can be very personal thing to anyone (close family member could have/had cancer etc.), the reasoning process towards the investment (in a cancer related stock) can be affected more by personal feelings and one’s desire to do charity. Comparing to other business areas that are available for investors. If this would be the case then following the money wouldn’t necessarily be the best strategy..

This is very speculative from me, my apologies. Just some thoughts.

H.C Wainwright conference will have recorded presentations. Most likely there will not be RNS related to this on Monday.

RNS might still be on it’s way during January because there is Proactive One2One booked. Of course it could be only a status update/reassuring interview, who knows. If there isn’t anything about Bex it would be nice to hear some background about Traumakine and it’s prolonged schedule.

I have to agree with Donald that Karvonen leaving without transition period doesn’t sound good. Also it might be that they have been seeking for a replacement for a while now but haven’t found any? After all this is only a small cap firm.

It might be that Faron has a buyer for Traumakine or it might that they failed with Traumakine and that’s why Karvonen had to leave?

We’ll have more knowledge somewhere in future, hopefully soon!

It means a great deal for our little company that’s for sure. I’m glad that they created one slide about potential market size because this hasn’t been available previously.

The point that got my attention was the very last sentence on the strategy slide: ”Build several partnerships with world leading pharma companies”. Could this be the reason why Markku has been quiet about the licensing etc. They aren’t looking for buy-out or exclusive deals and big pharmas aren’t ready for anything else based on current data?

Hopefully they have the competence to produce this kind of deal(s).

Webcast timing was a little bit off because they simultaneously also published the new corporate presentation. Maybe Markku wanted to emphasize the scientific progress behind all of this one more time?

Itsall,

I was wondering the same about the breast removal operations and avoiding those..

I also crunched some numbers. Based on information published on May about Bex, Bex could have been treatment for roughly 4% of cancer patients world wide. Now when Bex is showing promising results also on hepatocellular carcinoma (40%) and breast cancer (40%) patients, the number is roughly 28%.

These are very rough numbers and I crunched these mainly for a personal perspective. Anyhow, a HUGE increase in the potential market.

Cancer statistics:
https://gco.iarc.fr/today/online-analysis-multi-bars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=total&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=1&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D

Hollmen Lab’s latest tweet isn’t ”really” about Faron or about the upcoming conferences because of the #minätutkin.

This hashtag has been kately used by many Finnish scientist as a counter-reaction to the Finnish government’s plan to cut science funding (funding granted by Suomen Akatemia) here in Finland. Anyhow, very exciting week coming up.

15:05 Cash situation: how long will the EUR 7 million cash register last in the light of current information? What solutions are being sought?
We are doing the business in a way that Faron’s market cap is growing faster and bigger than the amount of capital that is invested in Faron. This has been successful.
Verneri: How you measure this?
Markku: We know how much capital investors have invested and we compare this to our market cap.
About our cash register. We have been granted soft money from for example DoD which is not visible in our cash register because get access to the funds as we progress with the research. This was a little poorly informed in our webcast.

16:35 Dynamics of financing in a pharmaceutical company. In a traditional way good news always have a positive effect in the SP.
Dilution system in US stock market’s works exceptionally well but in Europe we have more conservative approach as we require facts before investment decisions. You are right about the fact that if we produce great results, such as our recent results where we got 30-40% DCR from the last-line patients which was a remarkable result in my perspective which we then bring forward to the regulators and will eventually lead to the marketing authorization application. (Markku got little bit carried away in this last sentence about the results and didn’t really answer to actual question).

Thanks all for your hard work and sharing the information towards to community. This is my way of thanking you :)

10:35 According to the latest release (25.8), the first patient has received Traumaquina in connection with HIBISCU phase 2/3. Can you illuminate the schedule more? On what schedule the remaining doses will be given and when the data may be available for publication
This is very pivotal/crucial research in the way because we are producing a research where we put Traumakine and steroids in a collision course. In our opinion we should always start with IFRN-b which is our naturally produced product and if it doesn’t help then to start the usage of steroids. We are hoping to get 10-15 research sites up and running (we have currently 5 already) so I would imagine that IT (Markku may be referring with this to the publishing information) would be around start of year 2022. Interim and the advice from the independent body how to proceed should be ready during H1 2022 at the latest.

11:50 Is it the case that there are no originator antibodies to the Clever-1 receptor that are being developed other than by Faron? What prevents biosimilars from developing?
According to our knowledge no. Our patents in USA and Japan, and I’m confident that later also in the Europe, protects the antibody - Clever-1 interaction. Our patent is valid till 2037. This is optimal protection and we have knowingly delayed patent application (with a slight risk which was a success) because our aim was to lengthen the parent is far in the future is possible.
Verneri: How much this patent can actually protect? Can somebody circumvent the patent?
Markku: Drug regulators are respecting the patents, so we’ll meet all the offenders in the court! That is the whole point of these patents. There has also been a conversation about that this type of development would be done with taxpayer’s money but we don’t see that it is possible yet.

13:40 Is it good for the common good when Celver-1 is one's hands? Very delicious situation for the investors of course.
This is a very interesting situation. We have developed this for 10-years and all the sudden when we get good results everybody are interested. (This was followed by an analogy to the children’s old story where somebody wants to bake a bread and ask for help for farming the grains, making the dough etc. Nobody is interested in anything else than the end product (bread) which is eatable). When we started the development, we believed so strongly in this (Clever-1) that we wanted to push forward with this. Also in drug development this goes little bit like popular culture and fashion. For example, now CD-47 molecule is getting all the attention and there was just a big purchase in this area.